Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21273606rdf:typepubmed:Citationlld:pubmed
pubmed-article:21273606lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C1168401lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C1706679lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:21273606lifeskim:mentionsumls-concept:C2828242lld:lifeskim
pubmed-article:21273606pubmed:issue1lld:pubmed
pubmed-article:21273606pubmed:dateCreated2011-1-28lld:pubmed
pubmed-article:21273606pubmed:abstractTextSaracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate saracatinib in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC).lld:pubmed
pubmed-article:21273606pubmed:languageenglld:pubmed
pubmed-article:21273606pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21273606pubmed:citationSubsetIMlld:pubmed
pubmed-article:21273606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21273606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21273606pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21273606pubmed:statusMEDLINElld:pubmed
pubmed-article:21273606pubmed:monthJanlld:pubmed
pubmed-article:21273606pubmed:issn1791-7530lld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:PfisterDavid...lld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:ShenRonglaiRlld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:CarlsonDianeDlld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:StambukHildaHlld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:FuryMatthew...lld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:BaxiShrujalSlld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:HaqueSofiaSlld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:KellyKatherin...lld:pubmed
pubmed-article:21273606pubmed:authorpubmed-author:LipsonBrynna...lld:pubmed
pubmed-article:21273606pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21273606pubmed:volume31lld:pubmed
pubmed-article:21273606pubmed:ownerNLMlld:pubmed
pubmed-article:21273606pubmed:authorsCompleteYlld:pubmed
pubmed-article:21273606pubmed:pagination249-53lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:meshHeadingpubmed-meshheading:21273606...lld:pubmed
pubmed-article:21273606pubmed:year2011lld:pubmed
pubmed-article:21273606pubmed:articleTitlePhase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).lld:pubmed
pubmed-article:21273606pubmed:affiliationHead and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.lld:pubmed
pubmed-article:21273606pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21273606pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed